Research Article
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease
Table 4
Poisson regression model for IBD-related admissions.
| Characteristic | Unadjusted IRR (95% CI) | Adjusted IRR (95% CI) |
| Type of drug coverage | | | Private | ref | ref | Public | 2.32 (1.27–4.25) | 2.30 (1.19–4.43) | Age | 0.99 (0.97–1.02) | 1.00 (0.97–1.03) | Age at IBD diagnosis | 0.99 (0.97–1.02) | 0.99 (0.96–1.03) | Sex | | | Male | ref | ref | Female | 2.97 (1.63–5.42) | 2.96 (1.60–5.47) | IBD subtype | | | Crohn’s disease | ref | ref | Ulcerative colitis | 0.77 (0.39–1.52) | 0.75 (0.37–1.53) | Immunomodulator use | 1.52 (0.79–2.94) | 1.28 (0.67–2.46) | Steroid dependent or refractory | 1.68 (0.92–3.06) | 1.76 (1.01–3.05) | Aggressive IBD phenotype | 0.86 (0.45–1.63) | 1.15 (0.60–2.20) | Median neighborhood income | | | 1st quintile | ref | ref | 2nd quintile | 1.10 (0.43–2.81) | 1.21 (0.53–2.75) | 3rd quintile | 0.62 (0.22–1.74) | 0.77 (0.32–1.84) | 4th quintile | 0.35 (0.12–1.01) | 0.46 (0.17–1.26) | 5th quintile | 0.83 (0.33–2.12) | 0.96 (0.43–2.12) |
|
|